OMERS ADMINISTRATION Corp Takes $1.44 Million Position in Krystal Biotech, Inc. $KRYS

OMERS ADMINISTRATION Corp bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 3,880 shares of the company’s stock, valued at approximately $1,442,000.

Several other institutional investors have also recently added to or reduced their stakes in KRYS. UMB Bank n.a. increased its stake in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. Optimize Financial Inc raised its holdings in Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after purchasing an additional 40 shares in the last quarter. Regal Investment Advisors LLC lifted its position in shares of Krystal Biotech by 1.0% during the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after buying an additional 44 shares during the last quarter. Torray Investment Partners LLC boosted its holdings in shares of Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock valued at $3,108,000 after buying an additional 47 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its holdings in shares of Krystal Biotech by 0.9% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock valued at $1,537,000 after buying an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $359.76 on Thursday. Krystal Biotech, Inc. has a 1-year low of $136.73 and a 1-year high of $382.54. The stock has a market cap of $10.65 billion, a P/E ratio of 45.08 and a beta of 0.53. The firm has a fifty day moving average price of $348.38 and a 200 day moving average price of $303.24.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Sell-side analysts expect that Krystal Biotech, Inc. will post 7.68 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 51,000 shares of company stock valued at $16,278,020 over the last quarter. 13.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

KRYS has been the topic of several research analyst reports. Evercore reiterated an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. TD Cowen lifted their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Finally, Bank of America boosted their target price on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $365.40.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.